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M.  tuberculosis. Additional studies with all four drugs 
should be performed to confirm our results as well as 
to determine the critical concentration of drugs re- 
quired, especially those of streptomycin and rifampin. 
If an automated system incorporating MGIT technology 
is made available, it may further enhance the 
performance. 
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Patients undergoing renal dialysis are at increased 
risk of hepatitis C virus (HCV) infection, depending 
on the duration of treatment, extended exposure to 
transfusion and possible nosocomial transmission. The 
reported [I] incidence of HCV infection in dialysis 
units in southern Europe, Japan and the USA ranges 
from 10% to 30%, while in northern Europe the 
incidence is lower, ranging from 1% to 9%. 
Information about HCV infections in the general 
African population is scant, with reported prevalence 
rates varying greatly in different countries, &om more 
than 10% in the pygmy population in Cameroon to 
0-1.5% in South Africa. Socio-economic factors as 
well as cultural tradition (such as cosmetic tattooing) are 
likely to be relevant to the observed variation. To our 
knowledge, no data are available for Sub-Saharan Africa 
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on HCV infection in dialysis patients. The only report 
from South Africa describes a prevalence of 21% of 
HCV antibody (Ab) reactive patients confirmed with 
RIBA second generation among 103 subjects [a]. No 
data on HCV R N A  and viral types were provided. 
In Senegal, Sarr et a1 [3] presented data on the 
seroprevalence of HCV in 43 patients suffering from 
histologically confirmed chronic hepatitis C. In their 
series, reactivity rate was 14% versus 2% in the control 
group. Interestingly, indicating a possible synergistic 
action of hepatitis B virus (HBV) and HCV. double 
positivity was found only in chronic hepatitis C 
patients. In this study, a striking proportion of patients 
(41.9%) tested negative for both HBV and HCV. 
The authors suggested an etiologic role for other 
carcinogenic factors: environmental, chemical or viral. 
Mbaye et a1 [l]  investigated patients with chronic 
hepatitis (two subjects), cirrhosis (24 subjects) and 
hepatocellular carcinoma (41 subjects) admitted to the 
H6pital Principal in Dakar. They confirmed the high 
circulation of HBV in Senegal (with 74.5% of the 
patients being HBV carriers and 20% among the 
controls) and the likely relevance of this virus in chronic 
liver diseases. Moreover, in 12 patients a double 
infection with hepatitis delta virus (HDV) was noticed. 
Unfortunately, no data on HCV were reported [4]. 
In our experience [4], anti-HCV Ab were found 
by third-generation ELISA in only five of 173 subjects 
belonging to the rural population of two villages in 
Senegal, and two of them were confirmed by supple- 
mentary test (RIBA 3.0-Ortho Diagnostics System, 
Raritan, New Jersey, USA). These subjects proved to 
be viremic by reverse transcription- polymerase chain 
reaction (RT-PCR). These data, obtained in a similar 
population with overlapping diseases in the same 
country, differ from those reported by Sarr et a1 [3] and 
by Coursaget et a1 [5] demonstrating a much lower 
incidence o fHCV (1.4% versus 14% and 4.1%, respec- 
tively). These discrepancies, partly attributable to the 
better performance of the third-generation assay, require 
further studies to provide a satisfactory explanation. 
To understand HCV prevalence better in Senegal, 
we decided to investigate the distribution of this virus 
in all Senegalese patients on maintenance hemodialysis 
by investigating their antibody status. 
Twenty-two patients (21 males and one female) 
with kidney diseases (nephroangiosclerosis, 12; rapidly 
progressive glomerulonephritis, 4; indeterminate, 4; 
nephrotic syndrome, 1; chronic glomerulonephritis, 1) 
belonging to the upper middle class of the urban 
society of Dakar were enrolled in the present study. 
The clinical features of the patients are shown in 
Table 1. Liver biopsy was not performed for ethical and 
medical reasons. The patients had a mean age of 47 years 
(38-65), their serum alanine aminotransferase (ALT) 
level, (mean and range of values) was 30 (1 1-60) IU/L, 
and their serum aspartate aminotransferase (AST) level 
(mean and range of values) was 30 (4-100) IU/L. 
Time on hemodialysis did not appear to be a major 
risk factor for seroconversion or active viral replication. 
Dialysis treatment had a mean duration of 3.5 (range 
1-6) years. The majority of subjects (18122) had 
normal AST and ALT levels, except for four patients, 
two of whom were HCV R N A  positive. 
The patients were tested for HBsAg and only two 
(9%) were positive, whereas all sera (100%) were anti- 
HBc IgG positive and 10 of them were also anti-HBs 
positive. All sera, in 1-mL aliquots, were stored frozen 
at -8OOC until use. 
Screening for anti-HCV antibodies was performed 
by a third-generation enzyme immunoadsorbent assay 
(EIA 3.0-Ortho Diagnostics System). 
Positive samples were confirmed by a second- 
generation recombinant immunoblot assay (RIBA I1 
-0rtho Diagnostics System) according to the manu- 
facturer’s instructions. 
In positive samples, evidence of viremia was sought 
by RT-PCR for HCV R N A  (HCV Amplicor, Roche, 
Basel, Switzerland). 
The R N A  in all positive serum samples was typed 
by INNO-LIPA I1 assay (Innogenetics, NV, Antwerp, 
Belgium). The test allows the determination of up 
to six HCV genotypes and their subtypes. It is based 
on variations found in the 5’ untranslated regions 
(5’ UTR) of the different HCV genotypes. Biotin- 
labeled amplified products are hybridized to probes, 
on a strip, which gives a perfect sequence match at 
5OoC, with high specificity. The biotin group is 
incorporated by employing a 5’-biotinylated primer 
during amplification. After hybridization, streptavidin 
labeled with alkaline phosphatase is added and binds to 
any biotinylated hybrid previously formed. Following 
incubation with BCIP/NBT chromogen, a purple- 
brown color will develop on positive bands only when 
there is a perfect match. The reactivity of an amplified 
fragment with one or more bands on the strips allows 
recognition of different HCV genotypes. 
Among the 22 patients examined, who were 
attending the two hemodialysis units in Dakar (H6pital 
Le Dantec and H6pital Principal), HCV Ab reactivity 
was found in 11 cases. 
All results positive in the screening test were 
confirmed by RIBA 11. 
HCV R N A  was detected in six of the 11 patients, 
a percentage positivity very close to that found by us in 
northern Italy. Dual infection (with HBV and HCV) 
was detected in one subject who was positive for 
HBsAg and HCV-RNA. 
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No. tested 
Gender (male/female) 
Age (years) 
AST (IU/L) 
ALT (IU/L) 
Pathology 
Nephroangiosclerosis 
Rapidly progressive 
glomerulonephritis 
Indeterminate nephropathy 
Nephrotic syndrome 
Chronic glomerulonephritis 
Duration of dialysis (years) 
Virologic results 
Ab anti-HCV positive 
RIBA positive 
HCV-RNA positive 
Genotype HCV 2ac 
Genotype HCV, unclassified 
22 
20/1 
12 (54.6%) 
4 (18.2%) 
4 (18.2%) 
1 (4.5%) 
1 (4.5%) 
11 (50.0%) 
11 (50.0%) 
6 (27.3%) 
3 (13.6%) 
3 (13.6%) 
Table 1 Characteristics and virologic results of dialysis 
patients investigated at HBpital Le Dantec and HBpital 
Principal, Dakar, Senegal 
The molecular epidemiologic data are of sub- 
stantial interest. In this group of patients, type 2 is 
predominant; the pattern of types is completely 
n Mean Range different from that in Europe and Japan, where types l a  
and l b  prevail. Additionally, a difference can be noted 
with the detection of types 4c and 5a in South Africa 
or type 4c (B-4f (B), previously found in Zaire [6] 
46.8 3&65 and Gabon [7].  The presence of non-typeable strains is 
30.0 11-60 intriguing, and the possibility of new types circulating 
30.2 in Senegal as has been described in other regions 
of Africa, such as Gabon and Nigeria [8,9], makes 
sequencing of the HCV genome worth attempting. 
4-100 
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3.5 1-6 
AST, aspartate aminotransferase; ALT, alanine aminotransferase. 
The predominant genotype was 2ac. It was not 
possible to differentiate between the two subtypes with 
the commercially available method used. It was of 
special interest that typing was impossible, in the 
remaining three cases, suggesting the circulation in 
Senegal of new subtypes of known types, or hitherto 
unknown additional types. The virologic results are 
shown in Table 1. 
To our knowledge this is the first report on HCV 
RNA detection and typing in the sera of all the patients 
on dialysis in an African country. In the two units 
examined, the epidemiology as measured by the 
percentage of patients infected (HCV Ab reactive) and 
the percentage with HCV viremia does not appear to 
differ significantly from what has been observed in 
European hospitals. 
In this population, biochemical liver functions 
(ALT and AST) appear to be in the normal ranges. The 
use of these surrogate markers, which are certainly 
technically simpler and less costly to perform, appears 
unsuitable to detect viral replication and for liver disease 
activity. 
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